IL142535A0 - Pharmaceutical compositions for the treatment of inflammation - Google Patents

Pharmaceutical compositions for the treatment of inflammation

Info

Publication number
IL142535A0
IL142535A0 IL14253501A IL14253501A IL142535A0 IL 142535 A0 IL142535 A0 IL 142535A0 IL 14253501 A IL14253501 A IL 14253501A IL 14253501 A IL14253501 A IL 14253501A IL 142535 A0 IL142535 A0 IL 142535A0
Authority
IL
Israel
Prior art keywords
sub
inflammation
treatment
pharmaceutical compositions
cis
Prior art date
Application number
IL14253501A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to IL14253501A priority Critical patent/IL142535A0/xx
Publication of IL142535A0 publication Critical patent/IL142535A0/xx
Priority to CA002442953A priority patent/CA2442953A1/en
Priority to DE60237148T priority patent/DE60237148D1/de
Priority to HU0303881A priority patent/HUP0303881A3/hu
Priority to EP02724588A priority patent/EP1385500B1/en
Priority to NZ528784A priority patent/NZ528784A/en
Priority to IL15822702A priority patent/IL158227A0/xx
Priority to US10/474,447 priority patent/US20060183797A1/en
Priority to AU2002255241A priority patent/AU2002255241B2/en
Priority to MXPA03009341A priority patent/MXPA03009341A/es
Priority to KR10-2003-7013310A priority patent/KR20030096312A/ko
Priority to AT02724588T priority patent/ATE475416T1/de
Priority to PL02366586A priority patent/PL366586A1/xx
Priority to CNB028114892A priority patent/CN100352433C/zh
Priority to JP2002580926A priority patent/JP2004525180A/ja
Priority to PCT/IL2002/000294 priority patent/WO2002083122A1/en
Priority to ZA200307783A priority patent/ZA200307783B/en
Priority to NO20034558A priority patent/NO20034558L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL14253501A 2001-04-11 2001-04-11 Pharmaceutical compositions for the treatment of inflammation IL142535A0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
IL14253501A IL142535A0 (en) 2001-04-11 2001-04-11 Pharmaceutical compositions for the treatment of inflammation
PCT/IL2002/000294 WO2002083122A1 (en) 2001-04-11 2002-04-11 Fatty alcohols and fatty acid esters useful for treatment of inflammation
AU2002255241A AU2002255241B2 (en) 2001-04-11 2002-04-11 Fatty alcohols and fatty acid esters useful for treatment of inflammation
KR10-2003-7013310A KR20030096312A (ko) 2001-04-11 2002-04-11 염증 치료를 위해 유용한 지방 알콜 및 지방산 에스테르
HU0303881A HUP0303881A3 (en) 2001-04-11 2002-04-11 Pharmaceutical compositions containing fatty alcohols and fatty acid esters useful for treatment of inflammation
EP02724588A EP1385500B1 (en) 2001-04-11 2002-04-11 Fatty alcohols and fatty acid esters useful for treatment of inflammation
NZ528784A NZ528784A (en) 2001-04-11 2002-04-11 Use of an immunomodulator comprising a saturated or cis-unsaturated C10-C18 fatty alcohol useful for treatment of inflammation or disease of the skin
IL15822702A IL158227A0 (en) 2001-04-11 2002-04-11 Fatty alcohols and fatty esters useful for treatment of inflammation
US10/474,447 US20060183797A1 (en) 2001-04-11 2002-04-11 Fatty alcohols and fatty acid esters useful for treatment of inflammation
CA002442953A CA2442953A1 (en) 2001-04-11 2002-04-11 Fatty alcohols and fatty acid esters useful for treatment of inflammation
MXPA03009341A MXPA03009341A (es) 2001-04-11 2002-04-11 ALCOHOLES GRASOS Y ESTERES DE ACIDOS GRASOS UTILES PARA EL TRATAMIENTO DE LA INFLAMACIoN.
DE60237148T DE60237148D1 (de) 2001-04-11 2002-04-11 Fettalkohole und fettsäureester zur behandlung von entzündungen
AT02724588T ATE475416T1 (de) 2001-04-11 2002-04-11 Fettalkohole und fettsäureester zur behandlung von entzündungen
PL02366586A PL366586A1 (en) 2001-04-11 2002-04-11 Fatty alcohols and fatty acid esters useful for treatment of inflammation
CNB028114892A CN100352433C (zh) 2001-04-11 2002-04-11 用于治疗炎症的脂肪醇和脂肪酸酯
JP2002580926A JP2004525180A (ja) 2001-04-11 2002-04-11 炎症の治療に有用な脂肪族アルコール及び脂肪酸エステル
ZA200307783A ZA200307783B (en) 2001-04-11 2003-10-06 Fatty alcohols and fatty acid esters useful for treatment of inflammation.
NO20034558A NO20034558L (no) 2001-04-11 2003-10-10 Fettalkoholer og fettsyreestere nyttige ved behandling av inflammasjon

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL14253501A IL142535A0 (en) 2001-04-11 2001-04-11 Pharmaceutical compositions for the treatment of inflammation

Publications (1)

Publication Number Publication Date
IL142535A0 true IL142535A0 (en) 2002-03-10

Family

ID=11075312

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14253501A IL142535A0 (en) 2001-04-11 2001-04-11 Pharmaceutical compositions for the treatment of inflammation

Country Status (17)

Country Link
US (1) US20060183797A1 (es)
EP (1) EP1385500B1 (es)
JP (1) JP2004525180A (es)
KR (1) KR20030096312A (es)
CN (1) CN100352433C (es)
AT (1) ATE475416T1 (es)
AU (1) AU2002255241B2 (es)
CA (1) CA2442953A1 (es)
DE (1) DE60237148D1 (es)
HU (1) HUP0303881A3 (es)
IL (1) IL142535A0 (es)
MX (1) MXPA03009341A (es)
NO (1) NO20034558L (es)
NZ (1) NZ528784A (es)
PL (1) PL366586A1 (es)
WO (1) WO2002083122A1 (es)
ZA (1) ZA200307783B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
SK12772003A3 (sk) 2001-04-18 2004-07-07 Prometic Biosciences Inc. Stredne dlhé mastné kyseliny, glyceridy a analógy ako faktory prežitia a aktivácie neutrofilov
CA2483105C (en) 2002-05-13 2011-05-10 Arexis Ab Autoimmune conditions and nadph oxidase defects
JP2006502213A (ja) 2002-10-10 2006-01-19 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 脂肪族アルコール類の塩基性エステルおよび抗炎症薬または免疫調整薬としての使用
DK1592416T3 (da) 2003-02-07 2009-04-20 Prometic Biosciences Inc Fedtsyrer med middel kædelængde, glycerider og analoger som stimulatorer af erythropoiesis
CA2519278C (en) * 2003-03-20 2012-06-05 Imagenetix, Inc. Esterified fatty acid composition
US20050158329A1 (en) 2004-01-21 2005-07-21 Ghosh Swapan K. Novel phytol derived immunoadjuvants and their use in vaccine formulations
WO2005112912A1 (en) * 2004-04-24 2005-12-01 Sang-Hee Kim Immunomoduating agent, anti-cancer agent and health food containing monoacetyldiacylglycerol derivatives
JP4954450B2 (ja) * 2004-06-14 2012-06-13 ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエス 弾性繊維形成の不全、欠損又は無秩序による病状に対処するための、リシルオキシダーゼのアイソフォームの活性の誘導
JP5337479B2 (ja) 2005-05-04 2013-11-06 プロノヴァ・バイオファーマ・ノルゲ・アーエス 新規化合物
JP5046926B2 (ja) * 2005-05-16 2012-10-10 日本水産株式会社 炎症性疾患予防又は治療剤
US7294739B1 (en) 2006-11-06 2007-11-13 Teva Pharmacaetical Industries Ltd. Basic amine esters or oleic acid and their use as anti-inflammatory or immunobodulatory agents
KR100787765B1 (ko) * 2006-11-07 2007-12-24 고려대학교 산학협력단 팔미트산을 포함하는 알츠하이머병의 예방 또는 치료용조성물
JP5275047B2 (ja) * 2007-01-31 2013-08-28 久光製薬株式会社 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
EP2117301A4 (en) * 2007-02-26 2010-04-14 Yeda Res & Dev USE OF LONG-CHAINED ALCOHOL DERIVATIVES FOR THE TREATMENT OF CIRCULAR HAIR LOSS
WO2008106092A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
EP2144618B1 (en) 2007-03-28 2013-05-15 Aker Biomarine ASA Bioeffective krill oil compositions
BRPI0818310A8 (pt) * 2007-11-02 2017-12-26 Prometic Biosciences Inc Glicerídeos e ácidos graxos de cadeia média como agentes nefroprotetores
US9239334B2 (en) * 2008-09-08 2016-01-19 President And Fellows Of Harvard College Fatty acid C16: 1N7-palmitoleate a lipokine and biomarker for metabolic status
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
EP2272383A1 (en) * 2009-06-22 2011-01-12 SBAE Industries NV Composition Comprising Omega-7 and/or Omega-4 Fatty Acids
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
US9993549B2 (en) 2013-10-31 2018-06-12 Hisamitsu Pharmaceutical Co., Inc. Adjuvant composition, adjuvant preparation containing same, and kit
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
KR102152850B1 (ko) * 2014-03-28 2020-09-07 주식회사 엘지생활건강 글리세린 지방산 유도체의 용도
WO2016128830A1 (en) 2015-02-11 2016-08-18 Aker Biomarine Antarctic As Lipid extraction processes
KR102515207B1 (ko) 2015-02-11 2023-03-29 에이커 바이오마린 앤탁틱 에이에스 지질 조성물
WO2016134150A1 (en) * 2015-02-18 2016-08-25 Tersus Life Sciences, LLC Methods for improving joint function
US11406616B2 (en) * 2016-06-08 2022-08-09 Sunregen Healthcare Ag Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
KR101817552B1 (ko) * 2016-10-13 2018-01-11 주식회사 엔지켐생명과학 모노아세틸디아실글리세롤 화합물을 함유하는 간염의 예방 또는 치료용 조성물
CN108853066A (zh) * 2018-09-20 2018-11-23 成都中医药大学 链式脂肪醇在制备抗炎、镇痛药物中的用途
CN112168812B (zh) * 2019-07-02 2022-07-08 瑞微（深圳）生物科技有限公司 棕榈油酸用于制备预防或治疗炎症性疾病的组合物的用途
CN114544783B (zh) * 2020-11-20 2024-01-30 上海交通大学医学院附属瑞金医院 一种预防银屑病复发的内源性代谢物组合

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US612700A (en) * 1898-10-18 Disk plow
US6458772B1 (en) * 1909-10-07 2002-10-01 Medivir Ab Prodrugs
US3592930A (en) * 1968-07-19 1971-07-13 Syntex Corp Moisture-deterioratable topical medicaments,particularly anti-inflammatory steroids,in a substantially non-aqueous fatty alcohol-propylene glycol vehicle
US4152423A (en) * 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
US4258029A (en) * 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
EP0160103B1 (en) * 1983-10-26 1990-06-20 Kanebo, Ltd. Proteinous emulsifier, process for its preparation, and emulsified cosmetic preparation containing same
CH679119A5 (es) * 1988-05-13 1991-12-31 Sandoz Ag
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5194451A (en) * 1989-11-02 1993-03-16 Katz David H Systemic anti-inflammatory treatment
IE904098A1 (en) * 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
TW355153B (en) * 1996-05-21 1999-04-01 Toshiba Machine Co Ltd A method for leveling abrasive cloth and device for the same
DK1001759T3 (da) * 1996-09-17 2005-10-10 Avanir Pharmaceuticals Virusinhibering med langkædede alkoholer, alkaner, fedtsyrer og amider
KR100657642B1 (ko) * 1996-10-11 2006-12-19 스카리스타 리미티드 에이코사펜타엔산 및/또는 스테아리돈산을 포함하여 이루어지는 오일
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US6210700B1 (en) * 1997-01-14 2001-04-03 Novartis Nutrition Ag Enhancement of transplant graft survival through nutritional immunomodulation with omega-9 fatty acid dietary supplement therapy
US6242426B1 (en) * 1997-07-25 2001-06-05 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
US6114337A (en) * 1998-11-27 2000-09-05 Pugliese; Peter T. Zwitteronic-fatty acid compounds having anti-inflammatory properties
EP0919230A1 (en) * 1997-12-01 1999-06-02 Societe Des Produits Nestle S.A. NMIFA's as anti-inflammatory agents in superficial mammal tissues
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US6118020A (en) * 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
DK1194109T3 (da) * 1999-06-25 2004-10-25 Durham Pharmaceuticals Ltd Topiske formuleringer omfattende hud-gennemtrængningsmidler samt anvendelse deraf
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
JP2006502213A (ja) * 2002-10-10 2006-01-19 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 脂肪族アルコール類の塩基性エステルおよび抗炎症薬または免疫調整薬としての使用

Also Published As

Publication number Publication date
WO2002083122A1 (en) 2002-10-24
HUP0303881A2 (hu) 2004-03-01
KR20030096312A (ko) 2003-12-24
MXPA03009341A (es) 2004-02-12
US20060183797A1 (en) 2006-08-17
NO20034558D0 (no) 2003-10-10
ZA200307783B (en) 2004-10-06
PL366586A1 (en) 2005-02-07
NO20034558L (no) 2003-12-10
AU2002255241B2 (en) 2007-08-02
JP2004525180A (ja) 2004-08-19
CA2442953A1 (en) 2002-10-24
EP1385500A1 (en) 2004-02-04
EP1385500A4 (en) 2004-12-29
EP1385500B1 (en) 2010-07-28
DE60237148D1 (de) 2010-09-09
ATE475416T1 (de) 2010-08-15
HUP0303881A3 (en) 2009-10-28
NZ528784A (en) 2007-06-29
CN100352433C (zh) 2007-12-05
CN1514723A (zh) 2004-07-21

Similar Documents

Publication Publication Date Title
IL142535A0 (en) Pharmaceutical compositions for the treatment of inflammation
DE60237358D1 (es)
TNSN01108A1 (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
WO2003013497A1 (fr) Compositions s'averant efficaces pour prevenir ou soulager des troubles ou maladies provoques par une hypofonction cerebrale
WO2002094210A3 (de) Kosmetische mittel
HK1102348A1 (en) Composition containing polyglycerol/medium-chain fatty acid ester
MY127430A (en) Solid lipid formulations comprising an inhibitor of lipases and a fatty acid ester of polyols
WO2000009639A3 (en) Fatty ester combinations
ATE279209T1 (de) Injizierbare pharmazeutische zusammensetzung zur systemischen verabreichung pharmakologisch aktiver wirkstoffe enthaltend mittelkettige triglyceride
IL210233A (en) Formulation of omega-3 fatty acid containing epa and dha and no other active ingredients other than omega-3 fatty acids
ATE422350T1 (de) Anisinsäure und glyceride enthaltende zusammensetzungen
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
AU5629701A (en) Pourable shortening composition
EP1408951A4 (en) ANTI-FLAMMABILITY FATTY ALCOHOLS AND FATTY ACID ESTERS AS ANTIGENS
CA2404480A1 (en) Compositions containing polycarbonate
AU2002323075A1 (en) New methods for the preparation of propylene glycol fatty acid esters
WO2002049582A3 (de) Kosmetische und dermatologische lichtschutzformulierungen mit einem gehalt an benzotriazolderivaten und oberflächenaktiven zitronensäureestern
WO2007008427A3 (en) Aerosol compositions and methods
DE60101509D1 (de) Cla-ester
IT1292126B1 (it) Esteri cerosi arricchiti in acidi grassi omega-3 insaturi,loro preparazione ed uso
IL144706A0 (en) Ether type lipid a-1 carboxylic acid analogue and pharmaceutical compositions containing the same
AU2002331561A1 (en) Low odor composition for lactate esters and other ester biosolvents